A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

World Journal of Gastroenterology

Volumn 16, Issue 5, 2010, Pages 547-553

  Darvish Damavandi, Mahnaz ^a   Nikfar, Shekoufeh ^b,c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Clinical trial; Irritable bowel syndrome; Mebeverine; Meta analysis; Placebo; Systematic review

Indexed keywords

MEBEVERINE; PLACEBO;

ABDOMINAL PAIN; ANALGESIA; CLINICAL EVALUATION; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IRRITABLE COLON; META ANALYSIS; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; TABLET FORMULATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WHEAT BRAN;

EID: 76549133482     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i5.547     Document Type: Review

References (32)

1. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a metaanalysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-1780
2. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials. Arch Med Sci 2008; 4: 71-76
3. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15: 1548-1553
4. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP. Recent Pat Endocr, Metab Immune Drug Discovery 2009; 3: 69-75
5. Mathew P, Bhatia SJ. Pathogenesis and management of irritable bowel syndrome. Trop Gastroenterol 2009; 30: 19-25
6. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643-650
7. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30: 884-901
8. Talley NJ. Drug therapy options for patients with irritable bowel syndrome. Am J Manag Care 2001; 7: S261-S267
9. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510
10. Ritchie JA, Truelove SC. Comparison of various treatments for irritable bowel syndrome. Br Med J 1980; 281: 1317-1319
11. Berthelot J, Centonze M. Controlled double blind trial of Duspatalin (mebeverine) against placebo, in the treatment of irritable colon. Gaz Med de France 1981; 85: 2341-2343
12. Prout BJ. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner 1983; 227: 1607-1608
13. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J 1965; 2: 848-851
14. Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med 1972; 2: 34-36
15. Eisenburg J, Kruis W, Schüssler P, Weinzierl M. [The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome] Fortschr Med 1978; 96: 2064-2070
16. Hürzeller Castamer JC. Functional colitis: A multi centre study with mebeverine in 380 patients. Der Inf Arzl 1986; 2: 54-56
17. Liem KS, Timmermans HS. Final report on a double-blind placebo controlled tolerance study of mebeverine in healthy volunteer subjects. 1973, Duphar Report No. 56638/1482/7
18. Lüttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980; 6: 437-443
19. Secco GB, Di Somma C, Arnulfo G, Ricci C. [Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon] Minerva Med 1983; 74: 699-702
20. Jadad A. Randomized controlled trials. London: BMJ Books, 1998
21. Kruis W, Weinzierl M, Schüssler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986; 34: 196-201
22. Tasman-Jones C. Mebeverine in patients with the irritable colon syndrome: double blind study. N Z Med J 1973; 77: 232-235
23. Enck P, Klosterhalfen S, Kruis W. [Determination of placebo effect in irritable bowel syndrome] Dtsch Med Wochenschr 2005; 130: 1934-1937
24. Gilbody JS, Fletcher CP, Hughes IW, Kidman SP. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract 2000; 54: 461-464
25. Inauen W, Halter F. Clinical efficacy, safety and tolerance of mebeverine slow release (200 mg) vs. mebeverine tablets in patients with irritable bowel syndrome. Drug Invest 1994; 8: 234-240
26. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-340
27. Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006; 24: 207-236
28. Boisson J, Coudert PH, Dupuis J, Laverdant CH, Toulet J. Long term tolerance of mebeverine. Actual Cardiol Angeiol Int (Paris) 1987; 16: 289-292
29. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008; 53: 108-115
30. Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-1427
31. Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, Lee SD. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2000; 15: 925-930
32. Van Outryve M, Mayeur S, Meeus MA, Rosillon D, Hendrickx B, Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther 1995; 20: 277-282